11th Jul 2011 07:00
11 July 2011
Toumaz Limited
Sensium disposable digital plaster receives FDA approval
Toumaz Limited (AIM: TMZ, 'Toumaz', or 'the Group'), a pioneer in low cost, ultra low power wireless communications technology, is pleased to announce that the Sensium disposable digital plaster has received 510(k) approval from the US Food and Drug Administration ('FDA') in the US.
The Group expects the initial launch of the product into hospitals in the US to take place as planned, before the end of the year.
Separately Toumaz has established a new Joint Venture with Dr Patrick Soon-Shiong's company, California Capital Equity to continue development, commercialisation and distribution of the Sensium disposable digital plaster in North America and worldwide - see separate announcement.
Professor Chris Toumazou, Toumaz Chief Executive, commented:
"To gain approval for the Sensium plaster, on schedule, is a milestone achievement for us and we are very excited about being able to launch the product as planned later this year."
Enquiries:
Toumaz Limited | 020 7355 0036 |
Chris Toumazou, Chief Executive Officer |
|
Patrick Stephansen, Chief Financial Officer |
|
|
|
FinnCap | 020 7600 1658 |
Charles Cunningham (Corporate Finance) |
|
Brian Patient (Corporate Broking) |
|
|
|
College Hill | 020 7457 2020 |
Adrian Duffield/Kay Larsen |
About Toumaz (www.toumaz.com)
Toumaz is pioneering low cost, ultra-low power wireless technologies for a wide range of markets including medical monitoring and internet-connected consumer devices.
Targeting the Healthcare market, Toumaz's licensable smart sensor interface and transceiver platform, Sensium, is a leader in real-time wireless monitoring of the body's vital signs. Sensium has the potential to transform medical monitoring and reduce the cost of healthcare by wirelessly connecting individuals to healthcare providers - simply, affordably and unobtrusively. For healthcare professionals, this creates new opportunities for pro-active monitoring and improved quality of care. For patients, it delivers new opportunities for lifestyle-compatible personalised healthcare.
Toumaz also uses its ultra low power expertise to design devices for wireless connectivity and internet-connected consumer products. Toumaz currently supplies FM/DAB radio chips and complete modules to leaders in the digital radio market, such as PURE.
Toumaz is an AIM listed company (AIM: TMZ) with development centres in Oxford, UK and Taipei City, Taiwan.
Related Shares:
FST.L